Bicara Therapeutics, Inc. (BCAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$23.17-0.73%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BCAX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -33.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BCAX — earnings miss
Dated 2026-08-11
and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Bicara's rising losses may show serious financial problems. This can hurt future funding.
Worry ifQ2 operating losses reported worse than -$60M.
Less concerning ifOperating losses were better than -$60M.
Why it matters: Starting this study could provide new insights into dosing strategies for ficerafusp alfa. It may enhance treatment options.
Supportive ifThe study begins as planned in Q3 2026, focusing on loading and maintenance dosing.
Worry ifThe study does not start in Q3 2026 or is delayed without a clear reason.
Why it matters: Having a strong cash position is crucial for funding trials and operations.
Supportive ifCash reserves must stay stable or increase to support operations through 2029.
Worry ifReports show cash reserves are falling or not enough to fund operations after 2026.
Why it matters: Enrollment progress is key for an analysis in mid-2027. This may help ficerafusp alfa get approved faster.
Supportive ifMany people have enrolled in the FORTIFI-HN01 trial by December 2026.
Worry ifEnrollment is lower than expected. This slows down the interim analysis.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$203 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $524 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,643 loss on $10,000 · 26.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Study results could help speed up approval for ficerafusp alfa.
Supportive ifGood results came from the FORTIFI-FLEX study by Q4 2026.
Worry ifThe FORTIFI-FLEX study had bad results or delays.
Why it matters: Another earnings miss would show ongoing problems in meeting financial goals. This could hurt trust from investors.
Worry ifQ2 earnings report shows a miss similar to the May 11 announcement.
Less concerning ifQ2 earnings report meets or exceeds expectations.
Why it matters: If the health care sector shows renewed growth, it may help Bicara's outlook.
Supportive ifHealth care revenue growth re-accelerates back toward its highs above 9%.
Worry ifRevenue growth is slowing down and is now below 9%.
Why it matters: Updates on funding plans are important for keeping operations running. Clear plans could help investor feelings.
Supportive ifManagement announces a clear plan to fund operations through the first half of 2029.
Worry ifNo updates or unclear funding plans for 2029.
Why it matters: A slowdown in sector growth may hurt Bicara's chances to raise funds and attract investors.
Worry ifSector revenue growth is lower than usual.
Less concerning ifSector revenue growth is higher than usual.
Why it matters: This data will show how well ficerafusp alfa works with pembrolizumab in treating HPV-negative HNSCC. Strong results could boost confidence in the drug's potential.
Supportive ifData shows higher survival rates than standard treatments. This was shared in the ASCO presentation.
Worry ifData shows no big change in survival compared to standard treatments.